CARDIMMUN

A new therapeutic antibody with a personalised medicine approach in cardiovascular disease

Coordinatore	ACADEMISCH ZIEKENHUIS LEIDEN    more  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Mr. Nome: Jaco Cognome: De Graaf Email: send email Telefono: 31715265150
Nazionalità Coordinatore	Netherlands [NL]
Sito del progetto	http://cardimmun.eu/
Totale costo	7˙785˙840 €
EC contributo	5˙995˙080 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-2
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-08-01   -   2016-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Mr. Nome: Jaco Cognome: De Graaf Email: send email Telefono: 31715265150	NL (LEIDEN)	coordinator	278˙320.00
2	ATHERA BIOTECHNOLOGIES AB  Organization address address: FOGDEVRETEN 2B city: SOLNA postcode: 171 65 contact info Titolo: Mrs. Nome: Carina Cognome: Schmidt Email: send email Telefono: +46 761938190	SE (SOLNA)	participant	3˙260˙200.00
3	CTC CLINICAL TRIAL CONSULTANTS AB  Organization address address: SVEAVAGEN 8 city: UPPSALA postcode: 752 36 contact info Titolo: Dr. Nome: Bengt Cognome: Dahlström Email: send email Telefono: +46 703108587	SE (UPPSALA)	participant	1˙935˙200.00
4	SMERUD MEDICAL RESEARCH INTERNATIONAL AS  Organization address address: DRAMMENSVEIEN 41 city: OSLO postcode: 271 contact info Titolo: Mr. Nome: Knut Cognome: Smerud Email: send email Telefono: +47 9089 2577	NO (OSLO)	participant	398˙600.00
5	TURUN YLIOPISTO  Organization address address: YLIOPISTONMAKI city: TURUN YLIOPISTO postcode: 20014 contact info Titolo: Dr. Nome: Mari Cognome: Riipinen Email: send email Telefono: 35823336054	FI (TURUN YLIOPISTO)	participant	122˙760.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The project, CARDIMMUN, aims to pursue development of the scientific findings from the FP6 project CVDImmune. Based on our patented discovery, that low levels of anti-PC (phosphorylcholine) indicate risk for future development of cardiovascular disease, we have developed both a diagnostic test (a marker to identify cardiovascular disease patients that are at high risk of secondary events) and a candidate drug - an innovative fully human monoclonal antibody antibody, PC-mAb - that can block vascular inflammation. Together, this forms a unique opportunity for a personalised medicine approach, with a companion diagnostic and a targeted intervention in an area that is still in great medical need, despite recent advances in therapy. PC-mAb is now ready for clinical development.

The project will be progressed, by a structured plan that brings together SMEs and selected academic partners, and integrates preclinical and clinical studies into a commercially viable and mature therapeutic modality. The 5 work packages will embrace concept testing in animal models using biomarkers applicable also in human disease, coronary flow reserve and glucose uptake in inflamed arteries, as well as required toxicity studies. Additionally, studies in man are planned that explores safety, pharmacokinetics, pharmacodynamics and indices of clinical efficacy, including a placebo-controlled Proof of Activity trial in patients.

Athera’s PC-mAb is targeting the market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. According to plan, the data will enable a business agreement with Athera and a partner (probably big pharma) to enter into larger scale clinical trials by early 2017. PC-mAb could then be launched on the market as a new drug, with clear block-buster potential, by year 2020.'